Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma The PROACT Clinical Trial

被引：5

作者：

Austin, David ^{[1
,2
]}

Maier, Rebecca H. ^{[1
,2
]}

Akhter, Nasima ^{[3
]}

Sayari, Mohammad ^{[4
]}

Ogundimu, Emmanuel ^{[4
]}

Maddox, Jamie M. ^{[5
]}

Vahabi, Sharareh ^{[6
]}

Humphreys, Alison C. ^{[7
]}

Graham, Janine ^{[7
,8
]}

Oxenham, Helen ^{[9
]}

Haney, Sophie ^{[7
,10
]}

Cresti, Nicola ^{[11
]}

Verrill, Mark ^{[11
]}

Osborne, Wendy ^{[11
]}

Wright, Kathryn L. ^{[11
,12
]}

Goranova, Rebecca ^{[13
]}

Bailey, James R. ^{[14
]}

Kalakonda, Nagesh ^{[15
]}

Macheta, Mac ^{[16
]}

Kilner, Mari F. ^{[17
]}

Young, Moya E. ^{[18
]}

Morley, Nick J. ^{[19
]}

Neelakantan, Pratap ^{[20
]}

Gilbert, Georgia ^{[1
]}

Thomas, Byju K. ^{[1
]}

Graham, Richard J. ^{[1
]}

Fujisawa, Takeshi ^{[21
]}

Mills, Nicholas L. ^{[21
]}

Hildreth, Victoria ^{[22
]}

Prichard, Jonathan ^{[22
]}

Kasim, Adetayo S. ^{[23
]}

Hancock, Helen C.

Plummer, Chris ^{[24
,25
]}

机构：

[1] South Tees Hosp NHS Fdn Trust, James Cook Univ Hosp, Acad Cardiovasc Unit, Marton Rd, Middlesbrough TS4 3BW, England

[2] Newcastle Univ, Populat Hlth Sci Inst, Newcastle Upon Tyne, England

[3] Teesside Univ, Sch Hlth & Life Sci, Middlesbrough, England

[4] Univ Durham, Durham Coll, Durham, England

[5] Teesside Univ, Dept Psychol, Middlesbrough TS1 3BX, England

[6] Univ Hosp Bristol & Weston NHS Fdn Trust, Bristol Heart Inst, Bristol, England

[7] South Tees Hosp NHS Fdn Trust, Middlesbrough, England

[8] North Tees & Hartlepool NHS Fdn Trust, Stockton On Tees, England

[9] North Tees & Hartlepool NHS Fdn Trust, Stockton On Tees, England

[10] Cty Durham & Darlington NHS Fdn Trust, Darlington, England

[11] Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Newcastle Upon Tyne, England

[12] South Tyneside & Sunderland NHS Fdn Trust, Sunderland, England

[13] Univ Hosp Plymouth NHS Trust, Derriford Hosp, Dept Microbiol, Plymouth, England

[14] Hull Univ Teaching Hosp NHS Trust, Castle Hill Hosp, Queens Ctr Oncol & Haematol, Dept Haematol, Kingston Upon Hull, England

[15] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, England

[16] Blackpool Teaching Hosp, Dept Haematol, Blackpool, England

[17] Northumbria Healthcare NHS Fdn Trust, Pathol Serv, North Shields, England

[18] East Kent Hosp Univ NHS Fdn Trust, Dept Haematol, Canterbury, England

[19] Sheffield Teaching Hosp NHS Fdn Trust, Dept Haematol, Sheffield, England

[20] Royal Berkshire NHS Fdn Trust, Radiol Dept, Reading, England

[21] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Scotland

[22] Newcastle Univ, Newcastle Clin Trials Unit, Newcastle Upon Tyne, England

[23] Univ Durham, Dept Anthropol, Durham, England

[24] Newcastle Upon Tyne NHS Fdn Trust, Dept Cardiol, Newcastle Upon Tyne, England

[25] Newcastle Univ, Fac Med Sci, Newcastle Upon Tyne, England

来源：

JACC: CARDIOONCOLOGY | 2024年 / 6卷 / 05期

关键词：

anthracycline; biomarkers; breast cancer; echocardiography; lymphoma; prevention; INDUCED CARDIOTOXICITY; DYSFUNCTION; ENALAPRIL; DOXORUBICIN; INHIBITION; TOXICITY; THERAPY;

D O I：

10.1016/j.jaccao.2024.07.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Cardiotoxicity is a concern for cancer survivors undergoing anthracycline chemotherapy. Enalapril has been explored for its potential to mitigate cardiotoxicity in cancer patients. The dose-dependent cardiotoxicity effects of anthracyclines can be detected early through the biomarker cardiac troponin. Objectives The PROACT (Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma) clinical trial assessed the effectiveness of enalapril in preventing cardiotoxicity, manifesting as myocardial injury and cardiac function impairment, in patients undergoing high-dose anthracycline-based chemotherapy for breast cancer or non-Hodgkin lymphoma. Methods This prospective, multicenter, open-label, randomized controlled trial employed a superiority design with observer-blinded endpoints. A total of 111 participants, scheduled for 6 cycles of chemotherapy with a planned dose of >= 300 mg/m(2) doxorubicin equivalents, were randomized to receive either enalapril (titrated up to 20 mg daily) or standard care without enalapril. Results Myocardial injury, indicated by cardiac troponin T (>= 14 ng/L), during and 1 month after chemotherapy, was observed in 42 (77.8%) of 54 patients in the enalapril group vs 45 (83.3%) of 54 patients in the standard care group (OR: 0.65; 95% CI: 0.23-1.78). Injury detected by cardiac troponin I (>26.2 ng/L) occurred in 25 (47.2%) of 53 patients on enalapril compared with 24 (45.3%) of 53 in standard care (OR: 1.10; 95% CI: 0.50-2.38). A relative decline of more than 15% from baseline in left ventricular global longitudinal strain was observed in 10 (21.3%) of 47 patients on enalapril and 9 (21.9%) of 41 in standard care (OR: 0.95; 95% CI: 0.33-2.74). An absolute decline of >10% to <50% in left ventricular ejection fraction was seen in 2 (4.1%) of 49 patients on enalapril vs none in patients in standard care. Conclusions Adding enalapril to standard care during chemotherapy did not prevent cardiotoxicity in patients receiving high-dose anthracycline-based chemotherapy. (PROACT: Can we prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?; NCT03265574)

引用

页码：684 / 696

页数：13

共 50 条

[41] A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk
Vinayak, Shaveta
Schwartz, Erich J.
Jensen, Kristin
Lipson, Jafi
Alli, Elizabeth
McPherson, Lisa
Fernandez, Adrian M.
Sharma, Vandana B.
Staton, Ashley
Mills, Meredith A.
Schackmann, Elizabeth A.
Telli, Melinda L.
Kardashian, Ani
Ford, James M.
Kurian, Allison W.
BREAST CANCER RESEARCH AND TREATMENT, 2013, 142 (02) : 389 - 398
[42] Outcome of Breast Cancer Patients Treated outside of Clinical Trials
El Saghir, Nagi S.
Assi, Hussein A.
Jaber, Sara M.
Khoury, Katia E.
Nachef, Zahi
Mikdashi, Hana F.
El-Asmar, Nadine S.
Eid, Toufic A.
JOURNAL OF CANCER, 2014, 5 (06): : 491 - 498
[43] How to Follow, Manage and Treat Cardiac Dysfunction in Patients With Her2+Breast Cancer
Blaes, Anne
Manisty, Charlotte
Barac, Ana
JACC: CARDIOONCOLOGY, 2020, 2 (04): : 661 - 665
[44] Cardiac Monitoring and Heart Failure in Advanced Breast Cancer Patients Treated With Trastuzumab in Ontario, Canada
Rushton, Moira
Kappel, Coralea
Lima, Isac
Tuna, Meltem
Pritchard, Kathleen
Hawken, Steven
Dent, Susan
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
[45] Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: Preliminary results
Hardenbergh, PH
Munley, MT
Bentel, GC
Kedem, R
Borges-Neto, S
Hollis, D
Prosnitz, LR
Marks, LB
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 49 (04): : 1023 - 1028
[46] Effectiveness of exercise-based interventions in preventing cancer therapy-related cardiac dysfunction in patients with breast cancer: A systematic review and network meta-analysis
Zhang, Dandan
Xiong, Xingyu
Ding, Hexiao
He, Xiaole
Li, Huan
Yao, Yuzhi
Ma, Ruisi
Liu, Ting
INTERNATIONAL JOURNAL OF NURSING STUDIES, 2025, 163
[47] Mortality and Major Adverse Cardiac Events in Patients With Breast Cancer Receiving Radiotherapy: The First Decade
Jacobs, Johanna E. J.
L'Hoyes, Wouter
Lauwens, Lieselotte
Yu, Yu-Ling
Brusselmans, Marius
Weltens, Caroline
Voigt, Jens-Uwe
Wildiers, Hans
Neven, Patrick
Herrmann, Joerg
Thijs, Lutgarde
Staessen, Jan A.
Janssens, Stefan
Van Aelst, Lucas N. L.
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (08):
[48] Clinical importance of androgen receptor in breast cancer patients treated with adjuvant tamoxifen monotherapy
Honma, Naoko
Horii, Rie
Iwase, Takuji
Saji, Shigehira
Younes, Mamoun
Ito, Yoshinori
Akiyama, Futoshi
BREAST CANCER, 2013, 20 (04) : 323 - 330
[49] Association Between Cardiac Radiation Exposure and the Risk of Arrhythmia in Breast Cancer Patients Treated With Radiotherapy: A Case-Control Study
Errahmani, Mohamed Yassir
Locquet, Medea
Spoor, Daan
Jimenez, Gaelle
Camilleri, Jeremy
Bernier, Marie-Odile
Broggio, David
Monceau, Virginie
Ferrieres, Jean
Thariat, Juliette
Boveda, Serge
Kirova, Youlia
Loap, Pierre
Langendijk, Johannes A.
Crijns, Anne
Jacob, Sophie
FRONTIERS IN ONCOLOGY, 2022, 12
[50] Clinical Verification on the Predictors for Febrile Neutropenia in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
Goto, Wataru
Kashiwagi, Shinichiro
Matsuoka, Kohei
Iimori, Nozomi
Kouhashi, Rika
Yabumoto, Akimichi
Takada, Koji
Asano, Yuka
Tauchi, Yukie
Ogisawa, Kana
Morisaki, Tamami
Shibutani, Masatsune
Tanaka, Hiroaki
Maeda, Kiyoshi
ANTICANCER RESEARCH, 2023, 43 (01) : 247 - 254

← 1 2 3 4 5 →